search
Back to results

Topical Ethanol Extract (Piper Crocatum) for Anogenital Warts

Primary Purpose

Anogenital Wart

Status
Not yet recruiting
Phase
Not Applicable
Locations
Indonesia
Study Type
Interventional
Intervention
Topical Ethanol Extract (Piper crocatum)
Trichloroacetic Acid Topical
Sponsored by
Hasanuddin University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anogenital Wart focused on measuring Anogenital Wart, Trichloroacetic, Piper crocatum, Clinical Efficacy, Inflammatory Marker

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Men and women diagnosed with external anogenital warts Clinical lesions of Anogenital Wart at least 3 lesions with a size of 1-5 cm In patients with HIV, Cluster of Differentiation 4 (CD4)cell count >350 cells/mm and have been taking antiretroviral (ARV) drugs regularly for 3 months, Exclusion Criteria: Pregnant or lactating women Lesions located in the external urethral orifice and vagina Using systemic immunomodulators/immunosuppressants The protocol treatment will be discontinued if patients a. Withdraw their consent based on the patient's demand d. Severe adverse events occurred or allergies to the components of the test product b. After undergoing clinical trials, the patient experienced things that caused him/her to no longer meet the criteria set out in this protocol. c. Subjects do not comply the established study protocol

Sites / Locations

  • Wahidin Sudirohusodo General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention

Comparison

Arm Description

Daily topical application (twice/day, in the morning and 30-60 minutes before bed at night) for 56 days.

Weekly application (1x/week) by the physician for 8 weeks

Outcomes

Primary Outcome Measures

Size of wart
the size of wart measured from the outermost edge of the warts.
Foxp3+ regulatory T (Treg)
the expression of Foxp3+ regulatory T (Treg) from the stained T cells in anogenital wart lesion
TGF-β1
the expression of TGF-β1 from the stained cells in anogenital wart lesion
IFN-γ
the expression of IFN-γ from the stained cells in anogenital wart lesion

Secondary Outcome Measures

Full Information

First Posted
November 14, 2022
Last Updated
November 14, 2022
Sponsor
Hasanuddin University
search

1. Study Identification

Unique Protocol Identification Number
NCT05622916
Brief Title
Topical Ethanol Extract (Piper Crocatum) for Anogenital Warts
Official Title
The Efficacy of Ethanol Extract of Red Betel Leaves (Piper Crocatum) as Topical Patient-Applied Therapy In Anogenital Warts The Study of Foxp3+ Treg, Tumor Growth Factor (TGF)-β1, and Interferon (IFN)-γ Expression
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 30, 2022 (Anticipated)
Primary Completion Date
February 28, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hasanuddin University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial aims to assess the efficacy of topical Piper crocatum in treating Anogenital warts. It aims to answer the clinical efficacy of treating anogenital warts the expression of Foxp3+ regulatory T (Treg), TGF/Tumor Growth Factor -β1, and IFN/interferon -γ of anogenital wart lesion Participants will be allocated into two topical treatments, intervention and active comparator Trichloroacetic Acid (TCA) 90%. The researchers assume that intervention is superior compared to TCA 90%
Detailed Description
Study Design : A randomized controlled trial Population: Diagnosed with Condyloma Acuminata (International Classification of Disease 10 code A.63.0) Intervention period : 8 weeks of daily topical intervention with follow-up at week 12 Detailed formulation Extraction of Piper crocatum with ethanol assisted in a microwave-assisted extraction (MAE) The dissolution and active substances are separated by evaporation using a rotary evaporator to obtain the extract in the form of a thick solution freeze-drying is performed to obtain a stable thick extract preparation of ointment by adding formulation of ethanol extract of red betel leaves with 50 mg of white vaseline to achieve 30% concentration Settings: Outpatient care at the designated hospital Participants: Consecutive recruitment Sample Size Estimation: Following the formula of two different means, with the indicator, as follows: Type 1 error 5% Power of Study 80% Assuming the effect size of cohen d (in reducing the size of warts) is 0.5 equal allocation between two arms total sample: 100 participants Proposed analysis: Intention to treat (ITT) with sensitivity and subgroup analysis

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anogenital Wart
Keywords
Anogenital Wart, Trichloroacetic, Piper crocatum, Clinical Efficacy, Inflammatory Marker

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
One group will receive the intervention, whereas the comparison group will receive standard care
Masking
Participant
Masking Description
participants will be blind from the allocation by mimicking the topical solution
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Daily topical application (twice/day, in the morning and 30-60 minutes before bed at night) for 56 days.
Arm Title
Comparison
Arm Type
Active Comparator
Arm Description
Weekly application (1x/week) by the physician for 8 weeks
Intervention Type
Drug
Intervention Name(s)
Topical Ethanol Extract (Piper crocatum)
Other Intervention Name(s)
Red Betel Leaves
Intervention Description
Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
Intervention Type
Drug
Intervention Name(s)
Trichloroacetic Acid Topical
Other Intervention Name(s)
TCA 90
Intervention Description
Trichloroacetic acid topical 90%
Primary Outcome Measure Information:
Title
Size of wart
Description
the size of wart measured from the outermost edge of the warts.
Time Frame
Changes of wart size from baseline to week 12
Title
Foxp3+ regulatory T (Treg)
Description
the expression of Foxp3+ regulatory T (Treg) from the stained T cells in anogenital wart lesion
Time Frame
change of Foxp3+ regulatory T (Treg) expression from baseline to week 8
Title
TGF-β1
Description
the expression of TGF-β1 from the stained cells in anogenital wart lesion
Time Frame
change of TGF-β1 expression from baseline to week 8
Title
IFN-γ
Description
the expression of IFN-γ from the stained cells in anogenital wart lesion
Time Frame
change of IFN-γ expression from baseline to week 8
Other Pre-specified Outcome Measures:
Title
Adverse reaction
Description
any records of adverse reaction including inflammation, irritation or other systemic adverse event
Time Frame
any adverse event from baseline to week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women diagnosed with external anogenital warts Clinical lesions of Anogenital Wart at least 3 lesions with a size of 1-5 cm In patients with HIV, Cluster of Differentiation 4 (CD4)cell count >350 cells/mm and have been taking antiretroviral (ARV) drugs regularly for 3 months, Exclusion Criteria: Pregnant or lactating women Lesions located in the external urethral orifice and vagina Using systemic immunomodulators/immunosuppressants The protocol treatment will be discontinued if patients a. Withdraw their consent based on the patient's demand d. Severe adverse events occurred or allergies to the components of the test product b. After undergoing clinical trials, the patient experienced things that caused him/her to no longer meet the criteria set out in this protocol. c. Subjects do not comply the established study protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Idrianti Idrus, MD
Phone
+624118910174
Email
rasiah.05@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Idrianti Idrus, MD
Organizational Affiliation
Hasanuddin University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wresti Indriatmi, MD. Ph.D
Organizational Affiliation
Indonesia University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Fransiscus Suyatna, MD. Ph.D
Organizational Affiliation
Indonesia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wahidin Sudirohusodo General Hospital
City
Makassar
State/Province
South Sulawesi
ZIP/Postal Code
76124
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Agussalim Bukhari, MD, Ph.D.
Phone
+62 411 583333
Email
fkunhas@med.unhas.ac.id
First Name & Middle Initial & Last Name & Degree
Idrianti Idrus, MD
First Name & Middle Initial & Last Name & Degree
Wresti Indriatmi, MD, PhD
First Name & Middle Initial & Last Name & Degree
Franciscus D Suyatna, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
de-identified data will be shared for specific purpose, including article review
Citations:
PubMed Identifier
17609022
Citation
Sherrard J, Riddell L. Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts. Int J STD AIDS. 2007 Jun;18(6):365-8. doi: 10.1258/095646207781024711.
Results Reference
background
PubMed Identifier
32735077
Citation
Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1644-1653. doi: 10.1111/jdv.16522.
Results Reference
background
PubMed Identifier
24330738
Citation
Sazwi NN, Nalina T, Abdul Rahim ZH. Antioxidant and cytoprotective activities of Piper betle, Areca catechu, Uncaria gambir and betel quid with and without calcium hydroxide. BMC Complement Altern Med. 2013 Dec 11;13:351. doi: 10.1186/1472-6882-13-351.
Results Reference
background
Citation
Pharm T, Hartini YS, Wahyuono S, Widyarini S, Yuswanto A. Hartini et al In vivo Immunomodulatory Effect and Histopathological Features of Mouse Liver and Kidney Treated with Neolignans Isolated from Red Betel (Piper crocatum Ruiz & Pav) Leaf. Tropical Journal of Pharmaceutical Research. 2014;13:1609-1614. doi:10.4314/tjpr.v13i10.6
Results Reference
background
PubMed Identifier
30192406
Citation
Bonin CM, Padovani CTJ, da Costa IP, Avila LS, Ferreira AMT, Fernandes CES, Dos Santos AR, Tozetti IA. Detection of regulatory T cell phenotypic markers and cytokines in patients with human papillomavirus infection. J Med Virol. 2019 Feb;91(2):317-325. doi: 10.1002/jmv.25312. Epub 2018 Sep 24.
Results Reference
background
PubMed Identifier
19077104
Citation
Xu Y, Zhu KJ, Zhu N, Jiang DH, Chen XZ, Cheng H. Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum. Clin Exp Dermatol. 2009 Mar;34(2):229-35. doi: 10.1111/j.1365-2230.2008.03001.x. Epub 2008 Dec 2.
Results Reference
background

Learn more about this trial

Topical Ethanol Extract (Piper Crocatum) for Anogenital Warts

We'll reach out to this number within 24 hrs